Clinical trials of DC-based immunotherapy for RCC

Summary of the completed RCC clinical study and the data obtained:

RCC subjects were deficient in T cell IFN-gamma and IL-2 production pre-vaccination. The IL-2 defect was corrected in 7/12 patients post-vaccination. Vaccination resulted in an increase in tumor antigen-specific T cells in 8/12 patients. 7/12 subjects had a response to more than one antigen post-vaccination. Median overall survival was ~25 months compared to ~11 months for historical controls (confirmed by matched pair analysis).

• molecule type
• tumor associated antigen,
• Interleukin-2,
• Interferon gamma

• cell type
• T cell

• organism type
• Homo sapiens

• experimental design type
• in vivo design experiment

created over 16 years ago (2 March 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]